Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It works by blocking a protein (tumor necrosis factor or TNF) found in the body’s immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis.
Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. After treatment with adalimumab, a decrease in levels of acute phase reactant proteins of inflammation (C reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-6) was measured compared to baseline in patients diagnosed with rheumatoid arthritis.
This segment of the Adalimumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
- Abrilada: Pfizer
Abrilada is an FDA-approved biosimilar version of adalimumab. Abrilada (adalimumab-afzb) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose prefilled pen (Abrilada pen), as a single-dose 1 mL prefilled glass syringe, or as a single-dose institutional use vial. Enclosed within the pen is a single-dose 1 mL prefilled glass syringe. Though approved, it is not yet marketed in the US like several other manufacturers of approved biosimilar versions of adalimumab, Pfizer has signed a licensing agreement with AbbVie; under the agreement, Samsung would be able to launch the drug in November 2023.
- Halimatoz: Sandoz
Halimatoz is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Halimatoz contains the active substance adalimumab and is a ‘biosimilar medicine’. The active substance in Halimatoz, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF). TNF is involved in causing inflammation and is found at high levels in patients with the diseases that Halimatoz is used to treat. By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.
Further product details are provided in the report. Request sample pages @ Adalimumab Biosimilar Insight
- IBI303: Innovent Biologics
IBI303 is a recombinant human monoclonal antibody of TNF-α, which has the same amino acid sequence as branded adalimumab (Humira) and shows high degrees of similarity in respect to: chemical properties, in vitro biological activity (binding affinity and neutralizing activity against TNF-α), potency, and PK/PD. Pharmacologic and toxicologic studies of IBI303 also showed high similarity to Humira. Clinical studies have demonstrated that IBI303 can significantly alleviate the symptoms and physical signs of AS and decrease the disease activity and enthesitis, while improving both somatic motor ability and mobility of spine in patients with AS. It also improved the quality of life in patients with AS and reduced the disease’s impact on their activities of daily life. IBI303 also generated an acceptable safety profile with most of the adverse events graded as mild or moderate. IBI303 may meet Chinese patients’ urgent needs with an affordable price at global quality standards.
- CT-P17: Celltrion
CT-P17 is the first high-concentration type of medicine for a biosimilar made of adalimumab. The company has differentiated CT-P17 from existing Humira biosimilars by halving the dosage. By taking the latest trend into account, Celltrion has also removed citrate, which can cause pain in self-injection, from its latest product. If Celltrion launches CT-P17, it will be able to complete a robust portfolio of CT-P17 in the global autoimmune disorder treatment market.
Adalimumab: Therapeutic Assessment
This segment of the report provides insights about the different Adalimumab biosimilars segregated based on following parameters that define the scope of the report, such as:
- Major Players in Adalimumab
There are approx. 35+ key companies which are developing the therapies for Adalimumab.
Request sample pages @ Adalimumab Therapies
- The companies and academics are working to assess challenges and seek opportunities that could influence Adalimumab R&D. The therapies under development are focused on novel approaches to treat/improve Adalimumab.
- In July 2020, the FDA has approved an adalimumab biosimilar (Hulio) from Fujifilm Kyowa Kirin Biologics, making it the sixth adalimumab biosimilar to AbbVie’s reference product Humira that has been approved and the 28th biosimilar approved by the FDA. Mylan will handle the commercialization in the United States.
- In March 2020, Alvotech announced that it entered into an exclusive license partnership with DKSH, a market expansion services provider, for the commercialization of AVT02, a biosimilar to AbbVie’s HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets.
- In October 2018, Orion Corporation and Amgen have signed an agreement for the marketing and sales of AMGEVITA, Finland’s first adalimumab biosimilar. Based on its sales value, the original adalimumab product is the most-sold medicine globally and in Finland, and its impact on medicine reimbursement costs is substantial.
TABLE OF CONTENTS
1. Key Insights
2. Adalimumab Biosimilars: Snapshot
3. Executive Summary
3.2. The Basics of Biologics.
3.3. Biosimilars are not the Same as Generic Drugs
3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?
3.5. What Patients Need to Know About Biosimilars
4. Regulatory Outlook For Biosimilars
4.1. North America
4.3. Asia Pacific
4.3.4. South Korea
4.4. Rest Of The World
4.4.4. Saudi Arabia
*More Countries would be added in the final report
5. Adalimumab (Reference Product: Humira)
5.1. Drug Profile
5.2. Product Overview
5.3. Regulatory Approvals and Launch
5.5. Mechanism of Action
5.6. Dosage and Administration
5.7. Dosage and Strengths
5.8. Dose Modification
5.9. Route of Synthesis
5.13. Adverse Reactions
5.14. Product Snapshot
5.15. Development Milestones
6. Research and Development
6.1. Clinical Trials Information
6.2. Safety and Efficacy
7. Humira Biosimilar: Emerging Opportunities
8. Adalimumab: Biosimilars Assessment
8.1. Assessment by Product Type
8.2. Assessment by Route of Administration
8.3. Assessment by Molecule type
8.4. Sales Assessment
9. Adalimumab Biosimilars Profiles: By Company
184.108.40.206. Abrilada: Pfizer
220.127.116.11.1. Product Information
18.104.22.168.2. Research and Development
22.214.171.124.3. Other Development Activities
126.96.36.199.4. General Description Table
9.1.2. Innovent Biologics
188.8.131.52. IBI-303: Innovent Biologics
184.108.40.206.1. Product Information
220.127.116.11.2. Research and Development
18.104.22.168.3. Other Development Activities
22.214.171.124.4. General Description Table
126.96.36.199. CT-P17: Celltrion
188.8.131.52.1. Product Information
184.108.40.206.2. Research and Development
220.127.116.11.3. Other Development Activities
18.104.22.168.4. General Description Table
9.1.4. Shanghai Henlius Biotech
22.214.171.124. HLX 03: Shanghai Henlius Biotech
126.96.36.199.1. Product Information
188.8.131.52.2. Research and Development
184.108.40.206.3. Other Development Activities
220.127.116.11.4. General Description Table
18.104.22.168. Hyrimoz: Sandoz
22.214.171.124.1. Product Information
126.96.36.199.2. Research and Development
188.8.131.52.3. Other Development Activities
184.108.40.206.4. General Description Table
220.127.116.11. Halimatoz: Sandoz
18.104.22.168.1. Product Information
22.214.171.124.2. Research and Development
126.96.36.199.3. Other Development Activities
188.8.131.52.4. General Description Table
*More Companies and products would be added in the final report
10. Adalimumab Biosimilars: Comparative Landscape: By Company
11. Adalimumab Biosimilars: Competitive Landscape
11.1.2. Market Share Analysis
11.1.3. Competitive Scenario
184.108.40.206. Product Launches and approval
220.127.116.11. Partnerships, Collaborations and Agreements
18.104.22.168. Patent Expiration of Biologics
*More information would be added in the final report
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15.1. Research Methodology
15.1.2. Secondary Research
17. DelveInsight Capabilities
19. About DelveInsight